Effects of Fullerenol C60(OH)24 on Erythropoiesis in Vitro

Abstract

The effects of fullerenol C60(OH)24 in doses of 0.1-100 μg/ml on erythropoiesis were studied in the culture of erythroblastic islets of the bone marrow. Fullerenol in concentrations of 10 and 100 μg/ml had negative effects on the development of erythroid tissue: it inhibits proliferation of erythroid cells, delays erythroblast maturation, decelerates recruitment of erythroid CFU to differentiation, and suppresses repeated involvement of macrophages in erythroblastic islets.

Nanoquantitative Structure-Property Relationship Modeling on C42Fullerene Isomers

“…The analysis of the metrics associated with (5) and (6) leads to the conclusion that model given by (6) perform better than the model given by (5). The same conclusion is obtained by analyzing the plots of observed versus predicted TSE (Figure 4).…”

“…Since their discovery in 1985 [1], fullerenes attracted interest in different fields of science, including medical field (e.g., for potential use as antibiotics [2][3][4], as inhibitors of erythroid cells-fullerenol [5], as drug delivery system [6], or as inhibitors of inflammatory mediators [7]). Fullerene molecules are constructed from carbon atoms and take the shape of sphere (also known as buckyballs), ellipsoid, or tube [8].…”

Patent Highlights June–July 2017

“…This preparation (and hydroxy-fullerene without metal) was protective against UV-generated free hydroxyl radicals, and against a 6 Gy x-ray treatment administered as a radiation treatment of an experimental tumor induced by injecting H22 mouse hepatoma cells. These findings are particularly interesting because fullerenol in concentrations of 10 and 100 μg/ml has been reported to have negative effects on the development of erythroid tissue [48].…”

Potential Medical Use of Fullerenols After Two Decades of Oncology Research

“…Since this was the first study to investigate the effects of FRL on colon carcinogenesis in vivo, further studies would be required to evaluate its protective effect in other phases of carcinogenesis and to investigate the mechanism of its potential anticarcinogenic activity. All other studies investigating the cytostatic effects or cell apoptosis involving FRLs have been conducted on blood cell samples (erythrocytes) 113,116 or specific cancer cell lines. 9,15,[109][110][111][112][117][118][119][120] In most cases, FRL was proven to be strongly cytostatic and to induce cell apoptosis.…”

“…Other studies included in-vitro testing in different cell lines, such as ovarian (L929 112 ), liver (HepG2, 15,120 SMMC7721, 117 and BEL-7402 120 ), intestinal (Caco-2 114 ), lung (LLC1 9 ), breast (MDA-MB-231 9 ), melanoma (B16-F10 9 ), cervical (HeLa 109 ), kidney (LLC-PK1 118 ), and gastric (GES-1 111 ). In all in-vitro tests, FRL, alone 15,[110][111][112][113][114][115][117][118][119] or in conjugation with other medication, 9,19,116,120 showed significant cytostatic effects on cancer cells and a safety profile compared to healthy cells. Considering the discussion in the previous section related to the potential use of FRL in oncology, together with DOX as an organ-protector and/or synergistic cytostatic, 2 in-vitro studies related to the DOX-FRL complex would be interesting to review in greater details.…”